{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:03:16Z","timestamp":1760266996468,"version":"3.44.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.jneuroim.2009.12.012","type":"journal-article","created":{"date-parts":[[2010,1,26]],"date-time":"2010-01-26T04:59:17Z","timestamp":1264481957000},"page":"43-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Involvement of phosphodiesterases in autoimmune diseases"],"prefix":"10.1016","volume":"220","author":[{"given":"Keren","family":"Mizrachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revital","family":"Aricha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tali","family":"Feferman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neta","family":"Kela-Madar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Paperna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avraham","family":"Ben-Nun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Berrih-Aknin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam C.","family":"Souroujon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2009.12.012_bib1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0019-2791(77)90291-9","article-title":"Immunochemical studies on acetylcholine receptor from Torpedo californica","volume":"14","author":"Aharonov","year":"1977","journal-title":"Immunochemistry"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib2","first-page":"595","article-title":"Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory\/immunomodulatory drug potentially useful in some rheumatic diseases","volume":"22","author":"Anaya","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1096\/fj.05-4909fje","article-title":"Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor","volume":"20","author":"Aricha","year":"2006","journal-title":"Faseb J."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/ni1430","article-title":"CNS myeloid DCs presenting endogenous myelin peptides \u2018preferentially\u2019 polarize CD4+ T(H)-17 cells in relapsing EAE","volume":"8","author":"Bailey","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1189\/jlb.0505255","article-title":"Suppression of MIP-1beta transcription in human T cells is regulated by inducible cAMP early repressor (ICER)","volume":"79","author":"Barabitskaja","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cellsig.2003.08.009","article-title":"Differentiation of human monocytes in vitro with granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor produces distinct changes in cGMP phosphodiesterase expression","volume":"16","author":"Bender","year":"2004","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4049\/jimmunol.164.2.1117","article-title":"Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases","volume":"164","author":"Bielekova","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib9","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1084\/jem.20062129","article-title":"Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression","volume":"204","author":"Bopp","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V87.2.691.bloodjournal872691","article-title":"Interleukin-4 gene expression in activated human T lymphocytes is regulated by the cyclic adenosine monophosphate-dependent signaling pathway","volume":"87","author":"Borger","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib11","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.4049\/jimmunol.161.12.7015","article-title":"Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: an effect of the novel anti-inflammatory drug lisofylline","volume":"161","author":"Bright","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib12","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib13","first-page":"139","article-title":"Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species","volume":"2","author":"Deibler","year":"1972","journal-title":"Prep. Biochem."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3600143","article-title":"Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting","volume":"360","author":"Deval","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0192-0561(97)85556-7","article-title":"Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline","volume":"18","author":"D'Hellencourt","year":"1996","journal-title":"Int. J. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0165-5728(00)00265-4","article-title":"The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents","volume":"108","author":"Dinter","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1189\/jlb.71.4.588","article-title":"Effect of pentoxifylline on polarization and migration of human leukocytes","volume":"71","author":"Dominguez-Jimenez","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1027362629161","article-title":"Different regulatory effects of pentoxifylline on human T cell activation pathways","volume":"17","author":"Dong","year":"1997","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.4049\/jimmunol.159.3.1520","article-title":"Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein","volume":"159","author":"Ekholm","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2009.01.021","article-title":"Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3","volume":"209","author":"Feferman","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.4049\/jimmunol.167.3.1703","article-title":"Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness","volume":"167","author":"Fleming","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0165-5728(99)00063-6","article-title":"Treatment with BBB022A or rolipram stabilizes the blood\u2013brain barrier in experimental autoimmune encephalomyelitis: an additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors","volume":"97","author":"Folcik","year":"1999","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/ana.1218","article-title":"Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients","volume":"50","author":"Galboiz","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib24","first-page":"2382","article-title":"Pentoxifylline in the treatment of refractory nephrotic syndrome secondary to lupus nephritis","volume":"30","author":"Galindo-Rodriguez","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib25","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nature05543","article-title":"Foxp3-dependent programme of regulatory T-cell differentiation","volume":"445","author":"Gavin","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib26","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.300.2.559","article-title":"Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells","volume":"300","author":"Haddad","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/mus.20416","article-title":"Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy","volume":"32","author":"Hinkle","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jneuroim.2005.09.004","article-title":"The cytokine signature of MOG-specific CD4 cells in the EAE of C57BL\/6 mice","volume":"170","author":"Hofstetter","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib29","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.1016\/S0021-9258(19)38973-2","article-title":"Induction of a calcium\/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis","volume":"265","author":"Hurwitz","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0167-5699(88)91220-0","article-title":"The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response","volume":"9","author":"Kammer","year":"1988","journal-title":"Immunol. Today"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0006-2952(01)00688-8","article-title":"Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells","volume":"62","author":"Kanda","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1006\/bbrc.1995.1099","article-title":"Cyclic AMP is an essential factor in immune responses","volume":"206","author":"Koh","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1161\/01.CIR.104.2.197","article-title":"In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice","volume":"104","author":"Laurat","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib34","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.4049\/jimmunol.146.7.2245","article-title":"Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis","volume":"146","author":"Lennon","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1042\/BJ20051368","article-title":"Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies","volume":"393","author":"Lerner","year":"2006","journal-title":"Biochem. J."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib36","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.intimp.2008.05.012","article-title":"A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells","volume":"8","author":"Ma","year":"2008","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/jama.1994.03510250043028","article-title":"Pentoxifylline in the treatment of children with new-onset type I diabetes mellitus","volume":"271","author":"MacDonald","year":"1994","journal-title":"Jama"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib38","first-page":"625","article-title":"An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis","volume":"22","author":"Maksymowych","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jneuroim.2008.05.023","article-title":"Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent","volume":"201\u2013202","author":"Menon","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1124\/jpet.106.106096","article-title":"Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydrox ypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826, 141) prevents experimental autoimmune encephalomyelitis","volume":"319","author":"Moore","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib41","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.4049\/jimmunol.155.7.3693","article-title":"Pathogenicity of T cells responsive to diverse cryptic epitopes of myelin basic protein in the Lewis rat","volume":"155","author":"Mor","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib42","doi-asserted-by":"crossref","first-page":"E663","DOI":"10.1152\/ajpendo.2000.279.3.E663","article-title":"Role of adrenoceptors and cAMP on the catecholamine-induced inhibition of proteolysis in rat skeletal muscle","volume":"279","author":"Navegantes","year":"2000","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib43","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib44","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/nen.0b013e3181567c31","article-title":"Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis","volume":"66","author":"Reyes-Irisarri","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib45","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0165-5728(95)00176-X","article-title":"Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis","volume":"64","author":"Rieckmann","year":"1996","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib46","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/eji.1830230802","article-title":"Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats","volume":"23","author":"Rott","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/002215549904700707","article-title":"Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells","volume":"47","author":"Sadhu","year":"1999","journal-title":"J. Histochem. Cytochem."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib48","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood-2004-07-2729","article-title":"Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability","volume":"105","author":"Seybold","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib49","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000237693","article-title":"Cyclic AMP-elevating agents inhibit mite-antigen-induced IL-4 and IL-13 release from basophil-enriched leukocyte preparation","volume":"114","author":"Shichijo","year":"1997","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/PL00000198","article-title":"Effects of pentoxifylline and nabumetone on the serum levels of IL-1beta and TNFalpha in rats with adjuvant arthritis","volume":"49","author":"Silva","year":"2000","journal-title":"Inflamm. Res."},{"issue":"Suppl 2","key":"10.1016\/j.jneuroim.2009.12.012_bib51","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1703","article-title":"The role of the T cell in autoimmune inflammation","volume":"7","author":"Skapenko","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0165-5728(97)00111-2","article-title":"Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease","volume":"79","author":"Sommer","year":"1997","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib53","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2741\/2022","article-title":"Negative regulation of T-cell receptor activation by the cAMP-PKA-Csk signalling pathway in T-cell lipid rafts","volume":"11","author":"Tasken","year":"2006","journal-title":"Front. Biosci."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib54","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1042\/BST0340476","article-title":"The molecular machinery for cAMP-dependent immunomodulation in T-cells","volume":"34","author":"Tasken","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0898-6568(01)00214-5","article-title":"Molecular mechanisms for protein kinase A-mediated modulation of immune function","volume":"14","author":"Torgersen","year":"2002","journal-title":"Cell. Signal."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib56","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1212\/WNL.41.11.1836","article-title":"Myasthenia gravis: measurement of anti-AChR autoantibodies using cell line TE671","volume":"41","author":"Voltz","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2009.12.012_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0008-8749(91)90274-F","article-title":"Characterization of the 3\u2032,5\u2032-cyclic adenosine monophosphate-mediated regulation of IL2 production by T cells and Jurkat cells","volume":"135","author":"Wacholtz","year":"1991","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.jneuroim.2009.12.012_bib58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ana.21640","article-title":"The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?","volume":"65","author":"Weiner","year":"2009","journal-title":"Ann. Neurol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:13:01Z","timestamp":1759047181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572810000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":58,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0165572810000056"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2009.12.012","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involvement of phosphodiesterases in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2009.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}